Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021.
Euro Surveill
; 26(41)2021 10.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1470740
ABSTRACT
The Delta variant has become the dominant strain of SARS-CoV-2. We summarised the evidence on COVID-19 vaccine effectiveness (VE) identified in 17 studies that investigated VE against different endpoints. Pooled VE was 63.1% (95% confidence interval (CI) 40.9-76.9) against asymptomatic infection, 75.7% (95% CI 69.3-80.8) against symptomatic infection and 90.9% (95% CI 84.5-94.7) against hospitalisation. Compared with the Alpha variant, VE against mild outcomes was reduced by 10-20%, but fully maintained against severe COVID-19.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Vacunas contra la COVID-19
/
COVID-19
Tipo de estudio:
Estudio experimental
/
Revisiones
/
Revisión sistemática/Meta análisis
Tópicos:
Vacunas
/
Variantes
Límite:
Humanos
Idioma:
Inglés
Asunto de la revista:
Enfermedades Transmisibles
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
1560-7917.ES.2021.26.41.2100920
Similares
MEDLINE
...
LILACS
LIS